

## Supplementary Online Content

O'Brien EC, Mulder H, Jones WS, et al. Concordance between patient-reported health data and electronic health data in the ADAPTABLE trial. *JAMA Cardiol*. Published online November 2, 2022. doi:10.1001/jamacardio.2022.3844

**eFigure 1.** Inclusion Criteria for the ADAPTABLE Trial

**eTable 1.** Observed Concordance Between Patient-Reported and EHR-Derived Demographic Characteristics

**eTable 2.** Observed Concordance Between Patient-Reported and EHR-Derived Follow-up Events

**eTable 3.** Baseline Characteristics by First MI Event Concordance Status

**eTable 4.** Baseline Characteristics by First Stroke Event Concordance Status

**eTable 5.** Baseline Characteristics by First Revascularization Event Concordance Status

**eTable 6.** Baseline Characteristics by First Bleeding Event Concordance Status

**eTable 7.** Effect Estimates When Using Various Data Sources for Trial End Points

**eFigure 2.** Participant Portal Engagement and Event Exclusions

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure 1. Inclusion Criteria for the ADAPTABLE Trial**

<ul style="list-style-type: none"> <li>• Known atherosclerotic cardiovascular disease (ASCVD), defined by:             <ul style="list-style-type: none"> <li>○ Prior myocardial infarction</li> <li>○ Prior coronary angiography showing <math>\geq 75\%</math> stenosis of at least one epicardial coronary vessel</li> <li>○ Prior coronary revascularization procedures (either PCI or CABG)</li> <li>○ History of chronic heart disease, CAD, ASCVD</li> </ul> </li> <li>• Age <math>\geq 18</math> years</li> <li>• Receiving care in a participating health system</li> <li>• No known safety concerns or side effects considered to be related to aspirin, including             <ul style="list-style-type: none"> <li>○ No history of significant allergy to aspirin</li> <li>○ No history of significant GI bleed within the past 12 months</li> <li>○ Significant bleeding disorders that preclude the use of aspirin</li> </ul> </li> <li>• Access to the Internet</li> <li>• Not treated with warfarin, dabigatran, rivaroxaban, apixaban, edoxaban (current or planned)</li> <li>• Not treated with ticagrelor (current or planned)</li> <li>• Not pregnant or nursing</li> <li>• Estimated risk of a major cardiovascular event (MACE) <math>&gt; 8\%</math> over next 3 years, defined as the presence of at least one or more of the following enrichment factors:</li> </ul>	
<ul style="list-style-type: none"> <li>○ Age <math>&gt; 65</math> years</li> <li>○ Serum creatinine <math>&gt; 1.5</math> mg/dL</li> <li>○ Diabetes mellitus (Type 1 or Type 2)</li> <li>○ 3-vessel coronary artery disease</li> <li>○ Cerebrovascular disease and/or peripheral arterial disease</li> </ul>	<ul style="list-style-type: none"> <li>○ Left ventricular ejection fraction (LVEF) <math>&lt; 50\%</math></li> <li>○ Current cigarette smoker</li> <li>○ Chronic systolic or diastolic heart failure</li> <li>○ SBP <math>&gt; 140</math> in the past 12 months</li> <li>○ LDL <math>&gt; 130</math> in the past 12 months</li> </ul>

**eTable 1.** Observed Concordance Between Patient-Reported and EHR-Derived Demographic Characteristics

<b>Non-Hispanic White</b>				<b>Non-Hispanic Black</b>			
	<b>EHR</b>				<b>EHR</b>		
<b>Participant Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>	<b>Participant Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>
<i>Yes</i>	10966	66	11032	<i>Yes</i>	1198	24	1222
<i>No</i>	205	1784	1989	<i>No</i>	57	11742	11799
<i>Total</i>	11171	1850	13021	<i>Total</i>	1255	11766	13021
<b>Non-Hispanic Other</b>				<b>Hispanic</b>			
	<b>EHR</b>				<b>EHR</b>		
<b>Participant Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>	<b>Participant Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>
<i>Yes</i>	165	185	350	<i>Yes</i>	353	64	417
<i>No</i>	32	12639	12671	<i>No</i>	45	12559	12604
<i>Total</i>	197	12824	13021	<i>Total</i>	398	12623	13021
<b>Current Smoker</b>							
	<b>EHR</b>				<b>EHR</b>		
<b>Participant Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>				
<i>Yes</i>	745	190	935				
<i>No</i>	278	8726	9004				
<i>Total</i>	1023	8916	9939				

**eTable 2.** Observed Concordance Between Patient-Reported and EHR-Derived Follow-up Events

<b>Coronary Revascularization</b>				<b>Stroke</b>			
	<b>EHR</b>				<b>EHR</b>		
<b>Patient Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>	<b>Patient Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>
<i>Yes</i>	468	396	864	<i>Yes</i>	52	82	134
<i>No</i>	331	13466	13797	<i>No</i>	100	14427	14527
<i>Total</i>	799	13862	14661	<i>Total</i>	152	14509	14661
<b>Myocardial Infarction</b>				<b>Major Bleeding</b>			
	<b>EHR</b>				<b>EHR</b>		
<b>Patient Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>	<b>Patient Report</b>	<i>Yes</i>	<i>No</i>	<i>Total</i>
<i>Yes</i>	114	166	280	<i>Yes</i>	26	93	119
<i>No</i>	232	14149	14381	<i>No</i>	45	14497	14542
<i>Total</i>	346	14315	14661	<i>Total</i>	71	14590	14661

**eTable 3.** Baseline Characteristics by First MI Event Concordance Status

<b>Characteristic</b>	<b>Overall</b>	<b>Concordant Events</b>	<b>Discordant Events</b>
Age (yrs)			
N	14661	14263	398
Mean (SD)	66.7 (9.8)	66.7 (9.8)	66.5 (10.8)
Median (Q1 - Q3)	67.5 (60.7 - 73.5)	67.5 (60.7 - 73.5)	66.7 (59.6 - 73.5)
Min, Max	20.8, 98.6	20.8, 98.6	32.2, 91.4
Female	4594 (31.3%)	4463 (31.3%)	131 (32.9%)
Race			
White	11711 (80.9%)	11417 (81.1%)	294 (74.1%)
Black or African American	1295 (8.9%)	1236 (8.8%)	59 (14.9%)
Asian	144 (1.0%)	142 (1.0%)	2 (0.5%)
American Indian or Alaska native	112 (0.8%)	107 (0.8%)	5 (1.3%)
Multiple	130 (0.9%)	125 (0.9%)	5 (1.3%)
Other	395 (2.7%)	381 (2.7%)	14 (3.5%)
Opt out	687 (4.7%)	669 (4.8%)	18 (4.5%)
Ethnicity			
Hispanic	472 (3.3%)	454 (3.2%)	18 (4.5%)
Non-hispanic	13253 (91.6%)	12892 (91.6%)	361 (90.9%)
Opt out	749 (5.2%)	731 (5.2%)	18 (4.5%)
Current Smoker			
Missing	884 (6.0%)	867 (6.1%)	17 (4.3%)
No	12421 (84.7%)	12096 (84.8%)	325 (81.7%)
Yes	1356 (9.2%)	1300 (9.1%)	56 (14.1%)

**eTable 4.** Baseline Characteristics by First Stroke Event Concordance Status

<b>Characteristic</b>	<b>Overall</b>	<b>Concordant Events</b>	<b>Discordant Events</b>
Age (yrs)			
N	14661	14479	182
Mean (SD)	66.7 (9.8)	66.7 (9.8)	68.0 (10.0)
Median (Q1 - Q3)	67.5 (60.7 - 73.5)	67.5 (60.6 - 73.4)	68.1 (61.2 - 75.0)
Min, Max	20.8, 98.6	20.8, 97.3	40.6, 98.6
Female	4594 (31.3%)	4513 (31.2%)	81 (44.5%)
Race			
White	11711 (80.9%)	11578 (81.0%)	133 (73.5%)
Black or African American	1295 (8.9%)	1266 (8.9%)	29 (16.0%)
Asian	144 (1.0%)	143 (1.0%)	1 (0.6%)
American Indian or Alaska native	112 (0.8%)	111 (0.8%)	1 (0.6%)
Multiple	130 (0.9%)	129 (0.9%)	1 (0.6%)
Other	395 (2.7%)	385 (2.7%)	10 (5.5%)
Opt out	687 (4.7%)	681 (4.8%)	6 (3.3%)
Ethnicity			
Hispanic	472 (3.3%)	465 (3.3%)	7 (3.9%)
Non-hispanic	13253 (91.6%)	13086 (91.6%)	167 (92.3%)
Opt out	749 (5.2%)	742 (5.2%)	7 (3.9%)
Current Smoker			
Missing	884 (6.0%)	876 (6.1%)	8 (4.4%)
No	12421 (84.7%)	12265 (84.7%)	156 (85.7%)
Yes	1356 (9.2%)	1338 (9.2%)	18 (9.9%)

**eTable 5.** Baseline Characteristics by First Revascularization Event Concordance Status

<b>Characteristic</b>	<b>Overall</b>	<b>Concordant Events</b>	<b>Discordant Events</b>
Age (yrs)			
N	14661	13934	727
Mean (SD)	66.7 (9.8)	66.8 (9.8)	65.7 (9.8)
Median (Q1 - Q3)	67.5 (60.7 - 73.5)	67.6 (60.7 - 73.5)	66.0 (59.5 - 72.7)
Min, Max	20.8, 98.6	20.8, 98.6	33.7, 91.0
Female	4594 (31.3%)	4380 (31.4%)	214 (29.4%)
Race			
White	11711 (80.9%)	11172 (81.3%)	539 (74.4%)
Black or African American	1295 (8.9%)	1211 (8.8%)	84 (11.6%)
Asian	144 (1.0%)	138 (1.0%)	6 (0.8%)
American Indian or Alaska native	112 (0.8%)	104 (0.8%)	8 (1.1%)
Multiple	130 (0.9%)	118 (0.9%)	12 (1.7%)
Other	395 (2.7%)	374 (2.7%)	21 (2.9%)
Opt out	687 (4.7%)	633 (4.6%)	54 (7.5%)
Ethnicity			
Hispanic	472 (3.3%)	437 (3.2%)	35 (4.8%)
Non-hispanic	13253 (91.6%)	12613 (91.7%)	640 (88.4%)
Opt out	749 (5.2%)	700 (5.1%)	49 (6.8%)
Current Smoker			
Missing	884 (6.0%)	842 (6.0%)	42 (5.8%)
No	12421 (84.7%)	11836 (84.9%)	585 (80.5%)
Yes	1356 (9.2%)	1256 (9.0%)	100 (13.8%)

**eTable 6.** Baseline Characteristics by First Bleeding Event Concordance Status


<b>Characteristic</b>	<b>Overall</b>	<b>Concordant Events</b>	<b>Discordant Events</b>
Age (yrs)			
N	14661	14523	138
Mean (SD)	66.7 (9.8)	66.7 (9.8)	67.6 (10.4)
Median (Q1 - Q3)	67.5 (60.7 - 73.5)	67.5 (60.6 - 73.5)	66.4 (60.9 - 74.3)
Min, Max	20.8, 98.6	20.8, 98.6	37.5, 97.3
Female	4594 (31.3%)	4544 (31.3%)	50 (36.2%)
Race			
White	11711 (80.9%)	11612 (81.0%)	99 (71.7%)
Black or African American	1295 (8.9%)	1271 (8.9%)	24 (17.4%)
Asian	144 (1.0%)	143 (1.0%)	1 (0.7%)
American Indian or Alaska native	112 (0.8%)	112 (0.8%)	0 (0.0%)
Multiple	130 (0.9%)	128 (0.9%)	2 (1.4%)
Other	395 (2.7%)	390 (2.7%)	5 (3.6%)
Opt out	687 (4.7%)	680 (4.7%)	7 (5.1%)
Ethnicity			
Hispanic	472 (3.3%)	466 (3.3%)	6 (4.3%)
Non-hispanic	13253 (91.6%)	13132 (91.6%)	121 (87.7%)
Opt out	749 (5.2%)	738 (5.1%)	11 (8.0%)
Current Smoker			
Missing	884 (6.0%)	881 (6.1%)	3 (2.2%)
No	12421 (84.7%)	12302 (84.7%)	119 (86.2%)
Yes	1356 (9.2%)	1340 (9.2%)	16 (11.6%)



**eTable 7. Effect Estimates When Using Various Data Sources for Trial End Points**

<b>Data Source(s)</b>	<b>81 mg</b>	<b>325 mg</b>	<b>Hazard Ratio (95% CI) 81 vs 325</b>
EHR Only			0.98 (0.85 - 1.11)
N	7,329	7,332	
Rate <sup>1</sup> (events)	2.69 (430)	2.76 (433)	
Follow-up Time in Months [median (Q1, Q3)]	25.7 (18.1, 34.8)	25.2 (17.5, 34.3)	
Portal Only			0.91 (0.80 - 1.04)
N	7,540	7,536	
Rate <sup>1</sup> (events)	3.20 (448)	3.48 (471)	
Follow-up Time in Months [median (Q1, Q3)]	21.9 (14.1, 31.1)	21.2 (13.4, 30.5)	
EHR, Medicare, Private Claims, and Portal <sup>2</sup>			1.02 (0.91 - 1.14)
N	7,540	7,536	
Rate <sup>1</sup> (events)	3.62 (590)	3.55 (569)	
Follow-up Time in Months [median (Q1, Q3)]	25.5 (17.8, 34.4)	25.1 (17.5, 34.1)	

Supplemental tables and figure



**eFigure 2.** Participant Portal Engagement and Event Exclusions